Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|June 7, 2012
International variability in the reimbursement of cancer drugs by publically funded drug programsP K Cheema, S Gavura, M Migus, et al.Current Oncology (Toronto, Ont.)|April 25, 2015
Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in CanadaS Djalalov, J Beca, E Amir, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2006
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG)M E Trudeau, M Crump, D Charpentier, et al.Expert Opinion on Investigational Drugs|July 2, 2005
Docetaxel: a new active agent in the therapy of metastatic breast cancerP Fumoleau, A D Seidman, M E Trudeau, et al.Current Oncology (Toronto, Ont.)|April 26, 2014
Patients' perceptions of gene expression profiling in breast cancer treatment decisionsY Bombard, L Rozmovits, M E Trudeau, et al.Current Oncology (Toronto, Ont.)|March 12, 2019
Conditional approval of cancer drugs in Canada: accountability and impact on public fundingS K Andersen, N Penner, A Chambers, et al.Current Oncology (Toronto, Ont.)|April 8, 2015
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineO C Freedman, G G Fletcher, S Gandhi, et al.Current Oncology (Toronto, Ont.)|April 8, 2015
Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineA Eisen, G G Fletcher, S Gandhi, et al.Current Oncology (Toronto, Ont.)|April 8, 2015
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineS Gandhi, G G Fletcher, A Eisen, et al.Current Oncology (Toronto, Ont.)|April 8, 2015
Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineM Mates, G G Fletcher, O C Freedman, et al.Pageof 4